Intec Pharma Ltd.

110 articles about Intec Pharma Ltd.

• Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/12/2019

  Intec Pharma Ltd. announces financial results for the three and nine months ended September 30, 2019.

• Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society

  9/25/2019

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill® Carbidopa/Levodopa (AP-CD/LD), were presented yesterday at the International Congress of Parkinson's and Movement Disorder Society (MDS 2019) that was held from September 22-26, 2019 in Nice, France. 

• Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society

  9/16/2019

  Intec Pharma Ltd. announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa, will be presented at the upcoming International Congress of Parkinson's and Movement Disorder Society being held from September 22-26, 2019 in Nice, France.

• Intec Pharma to Participate in September Investment Conferences

  9/3/2019

  Intec Pharma Ltd. announces that Company management will participate at the following upcoming investment conferences in September.

• Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update

  8/9/2019

  Intec Pharma Ltd. announces financial results for the three and six months ended June 30, 2019.

• 

  Clinical Catch-up for July 22-26

  7/29/2019

  A number of companies reported clinical trial data last week. Here’s a look.

• Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

  7/22/2019

  Intec Pharma Ltd. announces top-line data from the Company's pivotal Phase 3 trial evaluating the safety and efficacy of the Accordion Pill®-Carbidopa/Levodopa compared with immediate release CD/LD as a treatment for the symptoms of advanced Parkinson's disease.

• 

  Intec Pharma Crashes as Phase III Parkinson’s Treatment Fails in Comparison Trial

  7/22/2019

  While the trial did not hit its goals, Intec said data review has shown that certain subsets of patients saw a meaningful reduction in OFF time.

• Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery

  7/1/2019

  Peer-reviewed journal article highlights unique oral delivery platform's ability to enhance pharmacokinetic and therapeutic benefit for challenging drugs

• Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

  6/25/2019

  Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients

• Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders

  6/19/2019

  Poster presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders taking place June 16-19, 2019 in Montreal, Canada. 

• Intec Pharma to Participate at June Investment Conferences

  5/28/2019

  Intec Pharma Ltd. announces that Company management will participate at the following upcoming investment conferences in June.

• Intec Pharma Granted European Patent

  5/20/2019

  Intec Pharma Ltd. announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF AN AGENT," and covers Intec's gastro-retentive drug delivery device with perforated external film.

• Intec Pharma Announces Research Collaboration Agreement With Merck

  5/16/2019

  Intec Pharma Ltd. announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to explore using the Accordion Pill® platform for an undisclosed development program.

• Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update

  5/7/2019

  Intec Pharma Ltd. announces financial results for the three months ended March 31, 2019 and provides a corporate update.

• Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders

  5/2/2019

  Intec Pharma Ltd. announces that the results from a pharmacokinetics study of the Accordion Pill™-Carbidopa/Levodopa 50/500 mg dosed three times per day was accepted for presentation in a poster at the upcoming XXIV World Congress on Parkinson's Disease and Related Disorders taking place June 16-19, 2019 at the Lyon Convention Centre in Montreal, Canada.

• Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients

  4/30/2019

  Company on track to report top-line data in July/August time frame

• Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference

  4/1/2019

  Intec Pharma Ltd. announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference.

• Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference

  3/13/2019

   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.

• Intec Pharma to Participate at Four Investment Conferences in March

  2/28/2019

  Intec Pharma today announces that Company management will participate at the following upcoming investment conferences in March.